logo
UPMC renames ICU to honor fallen Officer Andrew Duarte

UPMC renames ICU to honor fallen Officer Andrew Duarte

Yahoo14 hours ago

YORK, Pa. (WHTM) – The UPMC Memorial Hospital in York dedicated its Intensive Care Unit to Fallen West York Officer Andrew Duarte, who died during a mass shooting at the hospital in February.
'When you step off the elevator, you see his picture and his date of birth and death date,' Duarte's mother, Nancy Duarte Matarese said. 'I just look at it and that's my sweet child.'
Duarte's name is also above the ICU doors.
'He was an amazing young man,' Duarte's father, Gary Duarte said. 'From the day he was born, he did nothing but make us proud.'
Officers came from across the country, including Colorado, where Duarte used to serve as an officer.
Download the abc27 News+ app on your Roku, Amazon Fire TV Stick, and Apple TV devices
'He was a warrior, no doubt,' his former colleague, Lt. Alan Ma said. 'He was a true friend and a dear colleague.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)
IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)

Business Upturn

timean hour ago

  • Business Upturn

IOVA SHAREHOLDERS: Iovance Biotherapeutics, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 14 Deadline (NASDAQ:IOVA)

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619

Goose Creek PD to hold 7th annual Hot Pursuit 5K
Goose Creek PD to hold 7th annual Hot Pursuit 5K

Yahoo

time2 hours ago

  • Yahoo

Goose Creek PD to hold 7th annual Hot Pursuit 5K

GOOSE CREEK, S.C. (WCBD) – The Goose Creek Police Department will hold its 7th annual Hot Pursuit 5K this weekend. Money raised through the event will support some of the department's community-driven initiatives, like 'Operation Christmas Joy' and 'Shop with a Badge'. The race on Saturday will start near the municipal complex and traverse paved hiker/biker trails and roadways before returning to the complex. Roads along the race route will be closed to ensure the safety of participants and spectators. 'Our officers will permit vehicle traffic to pass when there is a lull in the runners; however, all drivers will have to drive away from the race route,' the department said. Saturday's race begins at 8 a.m. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Police investigate ‘officer-involved shooting' in Gresham
Police investigate ‘officer-involved shooting' in Gresham

Yahoo

time8 hours ago

  • Yahoo

Police investigate ‘officer-involved shooting' in Gresham

PORTLAND, Ore. () — Gresham police are investigating what they're calling an 'officer-involved shooting' Friday night. The Gresham Police Department announced in a that the shooting occurred near Northeast 165th Avenue and Northeast Glisan Street. Trendy SE Portland restaurant extends weekend hours Police said there is no ongoing threat to the community and more information will be released later. KOIN 6 News asked Gresham police for more information about the incident. We will update this story if they respond. This is a developing story. KOIN 6 News will update this story if more information becomes available. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store